There are currently 75 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
Hyperbaric Oxygen Therapy for Ulcerative Colitis
NCT05987852
Recruiting
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small mole... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/12/2024
Locations: University of Alabama Medicine, Birmingham, Alabama +14 locations
Conditions: Ulcerative Colitis
Register for Updates
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Hoag Hospital, Irvine, California +21 locations
Conditions: Ulcerative Colitis, Crohn Disease
Register for Updates
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT06094608
Recruiting
This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Register for Updates
Aquamin® as an Adjuvant Intervention for Ulcerative Colitis
NCT03869905
Recruiting
The purpose of this study is to determine if Aquamin® works as a potential treatment to improve symptoms and if it will induce remission in patients with mild Ulcerative Colitis and extend remission in Ulcerative Colitis in remission.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/05/2024
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Ulcerative Colitis
Register for Updates
GI Permeability Change in Response to Aquamin®
NCT04855799
Recruiting
This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/05/2024
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: Healthy, Ulcerative Colitis, Irritable Bowel Syndrome With Diarrhea
Register for Updates
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
NCT05370885
Recruiting
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2024
Locations: Digestive Health Specialists, Dothan, Alabama +52 locations
Conditions: Ulcerative Colitis, Colitis, Ulcerative
Register for Updates
Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
NCT06311123
Recruiting
The goal of this observational study is to learn about the mechanism of action of ozanimod in patients with ulcerative colitis (UC). The main questions it aims to answer are: Prospectively assess the effects of ozanimod on the cellular composition of intestinal lamina propria and blood by deep immunophenotyping (CyTOF) of immune cell subsets prior and after the drug's administration. Determine whether changes in cell subsets observed via mass cytometry correlate with with clinical or histologic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of California San Diego, San Diego, California
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona +67 locations
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
Nicotinamide Riboside in Ulcerative Colitis
NCT05561738
Recruiting
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/02/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis
Register for Updates
Fecal Microbiome Transplant
NCT02636517
Recruiting
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and aft... Read More
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
02/13/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Register for Updates
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
NCT05176366
Recruiting
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative colitis. Short Title: ExoFlo for ulcerative colitis Phase: 1 Methodology: Open label Study Duration: 24 months Subject Participation: 58 weeks Single or Multi-Site: Multi-Site
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Los Angeles, California +1 locations
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Register for Updates
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
NCT03669822
Recruiting
Ulcerative colitis (UC) is a chronic, progressive immunologically mediated disease affecting nearly 1 million Americans. Up to one third of patients with UC will require hospitalization for severe disease (termed 'acute severe colitis (ASUC)'), often within the first year after diagnosis. Investigators will develop a large multi-center cohort of patients with ASUC with homogeneously collected detailed longitudinal clinical and laboratory data.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2024
Locations: Joanna Melia, Baltimore, Maryland
Conditions: Ulcerative Colitis
Register for Updates